Business context and reporting period
The supplied filing is Nuvilex, Inc.’s unaudited Form 10-Q for the fiscal quarter ended January 31, 2014, with nine-month results compared with the nine months ended January 31, 2013. The request metadata names Pharmacyte Biotech, Inc.; that company name does not match the registrant identified in the filing.
Nuvilex had shifted its focus toward biotechnology, including Cell-in-a-Box live-cell encapsulation programs for pancreatic cancer and diabetes. It reported no material biotechnology revenue to date.
Key financial metrics
| Metric | Period / date | Reported value |
|---|---|---|
| Revenue | Nine months ended January 31, 2014 | $0 |
| Operating expenses | Nine months ended January 31, 2014 | $2.53 million |
| Operating loss | Nine months ended January 31, 2014 | $2.53 million |
| Net loss | Nine months ended January 31, 2014 | $10.78 million |
| Net loss | Three months ended January 31, 2014 | $458,772 |
| Cash and cash equivalents | January 31, 2014 | $864,895 |
| Total assets / total liabilities | January 31, 2014 | $5.66 million / $479,277 |
| Stockholders’ equity | January 31, 2014 | $5.18 million |
| Accumulated deficit | January 31, 2014 | $52.23 million |
| Net cash used in operating activities | Nine months ended January 31, 2014 | $616,468 |
| Net cash used in investing activities | Nine months ended January 31, 2014 | $2.55 million |
| Net cash provided by financing activities | Nine months ended January 31, 2014 | $3.83 million |
With no revenue in the current nine-month period, a current-period gross margin is not meaningful. The filing reports current liabilities of $479,277 and current assets of $1.54 million. The $20,000 note payable was past due at period-end; the filing says it was settled after January 31, 2014. The company also had $204,989 due to officers and directors and $34,834 of related-party accrued interest.
Material changes versus prior comparable periods
- Nine-month revenue fell from $12,160 to zero after the company discontinued Cinnergen sales because manufacturing and marketing costs exceeded revenue.
- Nine-month net loss increased from $1.27 million to $10.78 million. The increase principally reflected a $5.90 million loss on conversion of preferred stock and a $3.97 million loss on debt settlement, in addition to higher operating expenses.
- Nine-month operating expenses rose from $1.23 million to $2.53 million. Sales and marketing expense increased to $324,600, compensation expense to $955,060, and general and administrative expense to $529,950.
- Cash increased from $199,303 at April 30, 2013 to $864,895 at January 31, 2014, supported chiefly by equity financing. The company acquired biotechnology licenses and reported a $1.57 million investment in SG Austria.
- Shares outstanding increased from 482.1 million at April 30, 2013 to 603.0 million at January 31, 2014. The filing reports 638.3 million shares outstanding as of March 17, 2014.
Outlook, risks, contingencies and unusual items
Management planned to prepare for Phase 2b and Phase 3 trials for its pancreatic cancer treatment, conduct diabetes-related preclinical research, and pursue biotechnology partnerships and other business development. The filing provides no firm trial start dates, approval timetable, revenue forecast or quantified guidance.
The company disclosed substantial doubt about its ability to continue as a going concern: it had no regular revenue sufficient to cover operating costs, expected further losses, and depended on outside capital. It warned that failure to raise capital could delay or prevent clinical trials and could force it to modify or abandon plans or cease operations.
After quarter-end, Lincoln Park Capital purchased 8 million shares for $2 million and agreed, subject to contractual conditions and market-dependent sales, to purchase up to a further $25 million over 30 months. The company stated that it had approximately $4.0 million in its bank account as of March 17, 2014. These subsequent events are not included in January 31 cash.
Unusual reported items included the $5.90 million preferred-stock conversion loss and $3.97 million debt-settlement loss, partly offset by $1.63 million in gains on forgiveness of debt. The preferred-stock conversion involved 8,500 Series E shares converted into 54 million common shares. The company also reported issuing substantial shares for compensation and services. No material pending legal proceedings were reported; several disputes were settled during the period.
Important facts for investors to verify
- Confirm the issuer and filing period: the document names Nuvilex, Inc., and covers the quarter and nine months ended January 31, 2014.
- Review the terms, limits, registration conditions and actual drawdowns under the Lincoln Park Capital agreement; the $25 million commitment is not equivalent to cash already received.
- Verify the company’s post-quarter cash balance, subsequent share issuance and resulting dilution.
- Assess the clinical, regulatory, manufacturing and funding milestones required to advance the pancreatic cancer and diabetes programs.
- Check the accounting and valuation of the debt and preferred-stock conversion losses, license assets, related-party balances and stock-based compensation.
- Note a minor inconsistency in the MD&A: the prior-year quarterly net loss is stated there as $376,873, while the financial statements report $376,843.